Enfusion (NYSE:ENFN) Given Market Perform Rating at William Blair

Enfusion (NYSE:ENFN - Get Free Report)'s stock had its "market perform" rating restated by William Blair in a report released on Monday,Benzinga reports.

ENFN has been the subject of a number of other reports. Piper Sandler lifted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd. Stifel Nicolaus lifted their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Enfusion presently has a consensus rating of "Hold" and an average price target of $10.25.

Enfusion Price Performance

ENFN stock traded up $0.87 during mid-day trading on Monday, reaching $10.81. The company had a trading volume of 5,938,212 shares, compared to its average volume of 1,193,887. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of 270.32, a PEG ratio of 3.98 and a beta of 0.95. Enfusion has a 52 week low of $7.52 and a 52 week high of $11.38. The stock has a 50 day simple moving average of $10.15 and a two-hundred day simple moving average of $9.22.

Insider Buying and Selling at Enfusion

In other Enfusion news, CEO Oleg Movchan sold 2,771 shares of the company's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the sale, the chief executive officer now directly owns 526,702 shares in the company, valued at $5,335,491.26. This represents a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Bradley Herring sold 24,443 shares of Enfusion stock in a transaction on Friday, December 20th. The shares were sold at an average price of $10.61, for a total value of $259,340.23. Following the completion of the transaction, the chief financial officer now owns 270,503 shares in the company, valued at approximately $2,870,036.83. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,404 shares of company stock valued at $580,130 in the last quarter. Company insiders own 36.44% of the company's stock.

Institutional Investors Weigh In On Enfusion

Several hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of Enfusion by 612.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company's stock valued at $1,974,000 after acquiring an additional 178,821 shares during the period. Barclays PLC raised its holdings in shares of Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company's stock worth $817,000 after acquiring an additional 61,554 shares during the last quarter. Geode Capital Management LLC lifted its position in Enfusion by 7.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company's stock valued at $9,770,000 after acquiring an additional 70,367 shares in the last quarter. Wellington Management Group LLP boosted its stake in Enfusion by 6.7% during the 3rd quarter. Wellington Management Group LLP now owns 976,296 shares of the company's stock valued at $9,265,000 after purchasing an additional 61,032 shares during the last quarter. Finally, TenCore Partners LP bought a new stake in Enfusion during the 3rd quarter worth approximately $3,938,000. Institutional investors and hedge funds own 81.05% of the company's stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.